AMCP’s Annual Nexus Meeting to Feature New Outcomes Research from Analysis Group

October 15, 2021

Analysis Group’s Health Care practice will present eight posters at the Academy of Managed Care Pharmacy’s (AMCP’s) annual Nexus Meeting, which will be held October 18–21, 2021, in Denver, CO. Two of the abstracts received ribbon honors, including:

Silver ribbon

  • “Real-World Cost Burden of Blood Transfusions among Transfusion-Dependent Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Eculizumab in the US,” coauthored by an Analysis Group team – including Managing Principals Mei Sheng Duh and Mihran Yenikomshian, Vice President Wendy Y. Cheng, Senior Analyst Louise H. Yu, and Senior Research Professional Malena Mahendran – in collaboration with a team from Apellis Pharmaceuticals, Inc.

Bronze ribbon

  • “Impact of Blood Transfusions on Treatment Attributes, Quality of Life (QoL), and Out-of-Pocket (OOP) Costs in Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for High-Intensity Chemotherapy (HIC): Patient and Physician Perspectives,” coauthored by an Analysis Group team – including Vice Presidents Hongbo Yang and Yan Song, and Associate Mo Zhou – in collaboration with a team from Astellas Pharma Inc.

Additional poster presentations include:

  • “Real-World Utilization of Tenofovir-based Pre-Exposure Prophylaxis for the Prevention of HIV Infection in the US,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President François Laliberté, Manager Guillaume Germain, Associate Sean MacKnight, and Research Professional Annalise Hilts – in collaboration with a team from ViiV Healthcare.
  • “Estimating costs of adverse events (AEs) and healthcare resource use (HRU) in patients (pts) with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) receiving tisagenlecleucel and axicabtagene ciloleucel in real-world setting” coauthored by an Analysis Group team – including Vice President Hongbo Yang, Manager Jing Zhao, and Associate Su Zhang – in collaboration with a team from Novartis Pharmaceuticals.
  • “Healthcare resource use (HRU) by infusion setting of chimeric antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma (DLBCL) – a retrospective cohort study using CMS 100% Medicare database,” coauthored by an Analysis Group team – including Vice President Hongbo Yang, Manager Jing Zhao, and Senior Analyst Angie Lax – in collaboration with a team from Novartis Pharmaceuticals.
  • “Real-World Healthcare Resource Utilization and Costs Associated with Tisagenlecleucel and Axicabtagene Ciloleucel among Patients with Diffuse Large B-cell Lymphoma: An Analysis of Hospital Data,” coauthored by an Analysis Group team – including Vice President Hongbo Yang, Manager Jing Zhao, and Associate Qing Liu – in collaboration with a team from Novartis Pharmaceuticals.
  • “Depth of Prostate-Specific Antigen Response Among Patients with Metastatic Castration-Sensitive Prostate Cancer Treated with Apalutamide, Enzalutamide, or Abiraterone Acetate in a Community Urology Setting,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Dominic Pilon, Associate Carmine Rossi, and Senior Research Professional Frederic Kinkead – in collaboration with a team from Johnson & Johnson.
  • “Conventional therapy for ulcerative colitis: indicators of suboptimal treatment and associated healthcare costs,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice Presidents Marie-Hélène Lafeuille and Dominic Pilon, Associate Ameur Manceur, and Research Professional Maude Vermette-Laforme – in collaboration with a team from Johnson & Johnson.

Read more about AMCP Nexus 2021